Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 20/20 | 1.00 |
| ▸ | RARG | P13631 | 20/20 | 1.00 |
| ▸ | RARA | P10276 | 18/20 | 1.00 |
| ▸ | RXRA | P19793 | 9/20 | 0.87 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.70 |
| ▸ | GMNN | O75496 | 1/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | THPO | P40225 | 1/20 | 0.70 |
| ▸ | MTOR | P42345 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316404 | 1.00 | RARB (1.00) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL9145936 | 0.93 | RARB (0.87) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL9145943 | 0.93 | RARB (0.87) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL9007238 | 0.93 | RARB (1.00) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL9007232 | 0.93 | RARB (1.00) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL9147918 | 0.91 | RARB (0.83) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL9147910 | 0.91 | RARB (0.83) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL8460571 | 0.89 | RARB (0.80) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL8460567 | 0.89 | RARB (0.80) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL9143360 | 0.88 | RARB (0.78) | RARBRARGRARARXRAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993573-B2 | Chromane-substituted, tetrahydroquinoline-substituted and thiochromane-substituted heteroarotinoids as anti-cancer agents | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 2024-05-28 | — | — | US | disclosed |
| US-20210163415-A1 | CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 2021-06-03 | — | — | US | disclosed |
| US-10947198-B2 | Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroarotinoids as anti-cancer agents | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200062711-A1 | CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY | 2020-02-27 | — | — | US | disclosed |
| US-20100105757-A1 | TREATMENT AND INHIBITION OF DISEASE CONDITIONS USING FLEXIBLE HETEROAROTINOIDS | BENBROOK DORIS M | 2010-04-29 | — | — | US | disclosed |
| US-7612107-B2 | Such as cancer, diabetes, hemophilia, liver disease, diseases involving human aldehyde dehydrogenase 2, polycystic kidney disease, lysosomal storage diseases, high cholesterol, obesity, high triglycerides, glycoprotein metabolism, and angiogenesis | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2009-11-03 | — | — | US | disclosed |
| US-20060281806-A1 | Treatment and inhibition of disease conditions using flexible heteroarotinoids | BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA, THE | 2006-12-14 | — | — | US | disclosed |
| US-20060252817-A1 | Treatment and inhibition of disease conditions using flexible heteroarotinoids | BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA, THE | 2006-11-09 | — | — | US | disclosed |
| US-6586460-B1 | Administering heterocyclic ethers or sulfides to induce apoptosis, cell differentiation and as anticarcinogenic agents | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY | 2003-07-01 | — | — | US | disclosed |
| EP-0907646-B1 | DIHYDROBENZOPYRAN AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | UNIV VANDERBILT (US) | 2003-05-21 | — | — | EP | disclosed |
| US-6110960-A | FOR TREATING ARTHRITIS AND AS ANALGESIC | THE PROCTER & GAMBLE COMPANY (US) | 2000-08-29 | — | — | US | disclosed |
| EP-0907646-A1 | DIHYDROBENZOPYRAN AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-04-14 | — | — | EP | disclosed |
| WO-1998007716-A2 | HETEROAROTINOIDS-ANTICANCER AGENTS WITH RECEPTOR SPECIFICITY AND TGASE ACTIVITY | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 1998-02-26 | — | — | WO | disclosed |
| WO-1997046548-A1 | DIHYDROBENZOPYRAN AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 1997-12-11 | — | — | WO | disclosed |
| US-4826984-A | Heteroarotinoid compounds as anticancer agents | THE BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECHANICAL COLLEGE ACTING FOR AND ON BEHALF OF OKLAHOMA STATE UNIVERSITY (US) | 1989-05-02 | — | — | US | disclosed |
| US-4808597-A | Method for inhibiting the degradation of cartilage | PFIZER INC. (US) | 1989-02-28 | — | — | US | disclosed |
| EP-0130795-B1 | CARBOXYLIC ACID DERIVATIVES USEFUL FOR INHIBITING THE DEGRADATION OF CARTILAGE | PFIZER INC. (US) | 1988-11-23 | — | — | EP | disclosed |
| EP-0155940-A1 | BENZONORBORNENYL, BENZOPYRANYL AND BENZOTHIOPYRANYL RETINOIC ACID ANALOGUES | SRI INTERNATIONAL (US) | 1985-10-02 | — | — | EP | disclosed |
| WO-1985000806-A1 | BENZONORBORNENYL, BENZOPYRANYL AND BENZOTHIOPYRANYL RETINOIC ACID ANALOGUES | SRI INTERNATIONAL (US) | 1985-02-28 | — | — | WO | disclosed |
| EP-0130795-A2 | Carboxylic acid derivatives useful for inhibiting the degradation of cartilage | PFIZER INC. (US) | 1985-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163415-A1 | CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS | HCCS, CDYL, XPOT | RARB 2247/4885RARG 1949/4885RARA 2801/4885 |
| US-20100105757-A1 | TREATMENT AND INHIBITION OF DISEASE CONDITIONS USING FLEXIBLE HETEROAROTINOIDS | HSD17B4, HSD17B14, MAN2B1 | RARB 2862/4885RARG 2520/4885RARA 3000/4885 |
| US-10947198-B2 | Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroarotinoids as anti-cancer agents | HCCS, CDYL, XPOT | RARB 2247/4885RARG 1949/4885RARA 2801/4885 |
| US-20060281806-A1 | Treatment and inhibition of disease conditions using flexible heteroarotinoids | HSD17B4, HSD17B14, MAN2B1 | RARB 2862/4885RARG 2520/4885RARA 3000/4885 |
| US-20060252817-A1 | Treatment and inhibition of disease conditions using flexible heteroarotinoids | HSD17B14, HSD17B4, PNLIP | RARB 2002/4885RARG 1628/4885RARA 2067/4885 |
| US-11993573-B2 | Chromane-substituted, tetrahydroquinoline-substituted and thiochromane-substituted heteroarotinoids as anti-cancer agents | HCCS, CDYL, CDYL2 | RARB 1844/4885RARG 1801/4885RARA 2359/4885 |
| US-20200062711-A1 | CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS | HCCS, CDYL, XPOT | RARB 2247/4885RARG 1949/4885RARA 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.